Know What’s Real
Before You Book.
“Stem cell therapy” describes everything from bone marrow transplants that have saved lives for decades to injections sold in strip-mall clinics that no regulator has reviewed. They share a name, not a standard of proof — and a price tag rarely tells you which one you’re being offered. Before you commit to anything, find out what the product is, where the cells come from, and whether the FDA has approved it or cleared it for study. Talk to a coordinator who can match you with centers and trials that are willing to show their paperwork.
Federal Rules, Plainly
What the FDA
Actually Allows.
Most confusion about stem cell care comes down to one question: is the product approved, is it being studied with FDA permission, or is it being offered outside both? Here is how to read the labels.
A Biologics License Application is how the FDA approves a cell-based product. The list is short: cord-blood-derived blood-forming cells for certain blood and immune disorders, Omisirge for some blood cancer patients, and — since December 2024 — Ryoncil, the first approved mesenchymal stromal cell therapy, for children with steroid-refractory acute graft-versus-host disease.
Some human tissue products skip pre-approval if they’re minimally processed, used the way they naturally function, and not combined with other articles. Clinics often lean on this for fat, marrow, and birth-tissue products. Federal appeals courts in 2021 and 2024 rejected the argument for processed fat-derived cell mixtures (SVF).
An Investigational New Drug application is FDA permission to study a product in people; legitimate trials are listed on ClinicalTrials.gov. Florida’s SB 1768 (effective July 1, 2025) lets physicians offer some unapproved cell therapies for orthopedic, wound-care, and pain uses — but it doesn’t make them FDA-approved.
“Ask three things first: what is the product, where do the cells come from, and what is its FDA status?”
Know the Terrain
Where Stem Cell Care
Is Proven — and Isn’t.
The same two words cover very different things. This is a plain-language map of where cell therapy is established, where it’s still being tested, and where it’s mostly marketing.
Blood Cancers & Marrow Failure
Transplanting blood-forming stem cells — from your own body, a matched donor, or donated cord blood — is long-established care for leukemia, lymphoma, multiple myeloma, and some marrow failure conditions. It happens at accredited transplant programs, not walk-in clinics, and Medicare and many insurers cover medically necessary transplants.
Inherited Blood & Immune Disorders
Sickle cell disease, thalassemia, and certain inherited immune deficiencies can be treated with transplant. In December 2023 the FDA also approved the first gene therapies for sickle cell disease, which modify a patient’s own blood-forming stem cells. These are specialist-center treatments with defined eligibility.
Joint & Arthritis Pain
Knee, hip, and shoulder injections are the most heavily marketed use of stem cell products. The FDA says regenerative products have not been approved for any orthopedic condition, including osteoarthritis. Some are being studied in trials; many are sold outside them.
Back, Neck & Disc Problems
Degenerative disc pain attracts steady interest and some late-stage research, but no cell product is approved for it. Compare any offer against proven options first — and ask what the plan is if it doesn’t work.
Autoimmune & Neurological Conditions
Clinics advertise cell infusions for MS, Alzheimer’s, autism, and spinal cord injury; none of those uses is approved. Blood stem cell transplant is being studied for severe MS and some other autoimmune diseases in clinical trials and at select academic programs — a different thing from a clinic’s infusion.
Hair, Skin & Anti-Aging
Cosmetic stem cell and exosome products are widely marketed. The FDA has stated that no exosome products are approved. Treat “rejuvenation” claims as marketing until a registered trial says otherwise.
Before You Commit
Good Reasons to
Get a Second Look.
You don’t need a diagnosis in hand or a quote on the table. These are the situations that most often bring people to a first conversation.
Your doctor mentioned a transplant or cell therapy
Not every hospital runs a transplant program. Knowing which centers do, and which are accredited, is a useful first step.
A clinic quoted a price but couldn’t show an IND number
If a product isn’t approved, the clinic should be able to point to the FDA permission or registered trial behind it.
Standard options haven’t helped your pain
Physical therapy, steroid injections, and surgery come first for most conditions. If they haven’t worked, it’s fair to explore what else is credible.
A website says “FDA-registered” and you’re not sure what that means
Facility registration is a filing, not a product review. It’s worth decoding before it influences your decision.
You’d rather join a clinical trial than pay out of pocket
Trials have eligibility rules, oversight boards, and defined endpoints. Finding one that fits takes some digging.
You’re comparing costs and coverage
Transplants are often covered; most injections for joints, spine, and cosmetic uses are not. Get the numbers in writing first.
What Happens Next
From Question
to Consultation.
Every situation differs, but most requests follow a similar path. Here is the usual shape of it.
First Conversation
A coordinator listens to your diagnosis, what you’ve already tried, and what you’re hoping for — then explains whether you’re looking at an established transplant pathway, a clinical trial, or a clinic-based offering.
Records & Status Check
Imaging, lab work, and prior treatment notes are gathered. For any product under consideration, the coordinator helps confirm what it is, where the cells come from, and whether it’s approved, under an IND, or neither.
Options Matched
You’re introduced to centers that fit your situation: transplant programs, trial sites, or clinics willing to put product details and costs in writing. Getting a second opinion is encouraged.
Your Consultation
You meet the center, review the informed-consent documents, and see itemized costs, risks, and follow-up plans before deciding anything. Saying “not yet” is always an option.
Patient Notes
What People Tell Us
"I thought 'stem cell' meant one thing. Ten minutes on the phone and I knew which of the offers I'd been sent had real paperwork behind them."
"Nobody rushed me. They asked what my doctor had already tried, then pointed me to a trial I hadn't heard of."
"The quote I'd received never mentioned that it wasn't FDA-approved. Now I know what to ask, and when to walk away."
Straight Answers
Questions Worth Asking
For a narrow set of uses, yes. The approved products are blood-forming stem cell products made from cord blood for certain blood and immune-system disorders, Omisirge for some blood cancer patients, and Ryoncil, approved in December 2024 for children aged 2 months and older with steroid-refractory acute graft-versus-host disease. Bone marrow and blood stem cell transplants are established medical procedures as well. Beyond that, the FDA's consumer guidance says regenerative products have not been approved for orthopedic conditions such as osteoarthritis, tendonitis, or back, hip, knee, or shoulder pain. A coordinator can help you sort which category an offer falls into.
Usually it means a facility has listed itself with the FDA as a tissue establishment under 21 CFR Part 1271. That is a filing, not a review, and it says nothing about whether a specific product is safe or effective. Likewise, a clinic calling its product a "361" tissue product is describing how it thinks the FDA classifies it, not claiming the FDA examined it. The questions that matter are whether the product is FDA-approved and, if not, whether the clinic has an IND number or is enrolling you in a registered trial. Ask a coordinator to help you check.
Often, yes. Many clinics argue that using your own tissue in a single procedure places them outside FDA rules. Two federal appeals courts have rejected that argument for stromal vascular fraction, a mixture made by enzymatically breaking down fat: the Eleventh Circuit in United States v. U.S. Stem Cell Clinic (2021) and the Ninth Circuit in United States v. California Stem Cell Treatment Center (September 27, 2024). The Supreme Court later declined to hear the clinic's appeal. The FDA's consumer guidance also advises asking for an IND number even when the cells come from your own body. Talk to a coordinator about what to ask.
Look up the study's registration number on ClinicalTrials.gov and confirm that the sponsor, location, and eligibility criteria match what the clinic told you. Ask for the IND number and the name of the institutional review board overseeing the study. Be cautious if you're asked to pay large fees to take part, if results are promised, or if one product is offered for nearly every condition. The FDA also asks anyone considering an unapproved regenerative product to contact its Office of Communication, Outreach and Development at [email protected]. We can help you find trials that fit your situation.
The FDA has received reports of serious harm from unapproved products, including infections, tumor formation, and blindness after injections into the eye. Cells can also travel to unintended parts of the body or simply fail to work as hoped, and the CDC has documented bloodstream infections linked to unapproved stem cell injections. Approved products carry risks too: Ryoncil's labeling, for example, warns of infusion reactions and possible transmission of infectious agents. Problems can be reported to FDA MedWatch at 800-FDA-1088. A coordinator can walk you through questions to raise with any provider.
For established uses, often yes: Medicare covers stem cell transplants for certain conditions, and many private plans cover medically necessary transplants after review. For unapproved injections, which covers most joint, spine, aesthetic, and neurologic offerings, coverage is uncommon and the cost is typically paid out of pocket. Get quotes in writing, ask what is included (follow-up visits, repeat injections, complications), and check with your insurer before you commit. Ask us to match you with centers that itemize costs.
No. Florida's SB 1768, effective July 1, 2025, lets licensed physicians administer certain stem cell therapies that are not FDA-approved for orthopedic, wound-care, and pain-management uses, with written-consent and sourcing requirements, and a small number of other states have passed similar "right to try" style laws. A state law doesn't change how the FDA classifies the product or turn it into one with proven safety and benefit; it means the treatment may be legal to offer there. Ask the clinic what the product is, who made it, and what evidence supports its use for your condition. Start with a free consultation match.
Ask Before
You Pay.
A private conversation about your goals, your records, and your options — free, with no pressure to book anything.